Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec

European Journal of Human Genetics

Volumn 19, Issue 5, 2011, Pages 494-499

  Dorval, Michel ^a,b,c   Nogués, Catherine ^d   Berthet, Pascaline ^e   Chiquette, Jocelyne ^b,c   Gauthier Villars, Marion ^d   Lasset, Christine ^f   Picard, Claude ^d   Plante, Marie ^g   Brcas, Inherit ^a   Cohort, Genepso ^a   Simard, Jacques ^a,g   Julian Reynier, Claire ^h,i,j  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF QUEBEC   (Canada)

^c Centre des maladies du sein Desch nes Fabia   (Canada)

^d INSTITUT CURIE   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f CENTRE LÉON BÉRARD   (France)

^g LAVAL UNIVERSITY   (Canada)

^h INSERM   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

BRCA1 2; Breast cancer screening; Cohort study; Non carriers; Ovarian cancer screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SELF EXAMINATION; CANADA; CANCER SCREENING; CLINICAL EXAMINATION; ECHOGRAPHY; FEMALE; FOLLOW UP; FRANCE; GENE MUTATION; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL PRACTICE; OVARY CANCER; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; TRANSVAGINAL ECHOGRAPHY;

EID: 79955767109     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2010.227     Document Type: Article

References (31)

1. Offit K, Garber J, Grady M et al: ASCO Curriculum: Cancer Genetics & Cancer Predisposition Testing. Alexandria, VA: ASCO, 2004.
2. Korde LA, Mueller CM, Loud JT et al: No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. Breast Cancer Res Treat 2011; 125: 169-173.
3. Domchek SM, Gaudet MM, Stopfer JE et al: Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 2010; 119: 409-414.
4. Katki HA, Gail MH, Greene MH: Breast-cancer risk in BRCA-mutation- negative women from BRCA-mutation-positive families. Lancet Oncol 2007; 8: 1042-1043. (Pubitemid 350182956)
5. Berliner JL, Fay AM: Risk assessment and genetic counseling for hereditary breast and ovarian cancer: Recommendations of the National Society of Genetic Counselors. J Genet Counsel 2007; 16: 241-260. (Pubitemid 46878636)
6. Dawson SJ, Price MA, Jenkins MA et al: Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol 2008; 26: 225-232.
7. Foster C, Watson M, Eeles R et al: Predictive genetic testing for BRCA1/2 in a UK clinical cohort: Three-year follow-up. Br J Cancer 2007; 96: 718-724. (Pubitemid 46376618)
8. Eisinger F, Bressac B, Castaigne D et al: Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004). Bull Cancer 2004; 91: 219-237.
9. Horsman D, Wilson BJ, Avard D et al: Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can 2007; 29: 45-60.
10. Morrison B: Screening for Breast Cancer: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada, 1994, pp 788-795.
11. Agence Nationale d'Accréditation et d'É valuation en Santé : Le dépistage du cancer du sein par mammographie dans la population générale: Étude d'évaluation technologique. Paris: ANAES, 1999.
12. Andrieu N, Easton DF, Chang-Claude J et al: Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: A report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 2006; 24: 3361-3366. (Pubitemid 46638890)
13. Simard J, Dumont M, Moisan AM et al: Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French- Canadian families with high risk of breast and ovarian cancer. J Med Genet 2007; 44: 107-121.
14. Dorval M, Bouchard K, Maunsell E et al: Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: Comparison with control population. J Genet Counsel 2008; 17: 314-326.
15. SAS Institute: Statistical Analysis System Version 9.1. Cary, NC: SAS Institute, 2006.
16. Statistique Canada: Enquěte sur la santé dans les collectivités canadiennes Cycle 3.1 (2005): Fichier de microdonnées ágrande diffusion, Ottawa, Statistique Canada, 2006.
17. Duport N, Bloch J: Dépistage du cancer du sein; in Guilbert P, Peretti-Watel, Beck F, Gautier A (eds): Barométre Cancer 2005. Saint-Denis: INPES, 2006, pp 119-126.
18. Eisinger F, Alby N, Bremond A et al: Expertise collective INSERM-FNCLCC: Recommandations portant sur la prise en charge des femmes ayant un risque d'origine géné tique de développer un cancer du sein et/ou de l'ovaire. Bull Cancer 1999; 86: 307-313. (Pubitemid 29196092)
19. Leschot NJ, Vejerslev LO: Proceedings of the EUCROMIC workshop on prenatal diagnosis. Eur J Hum Genet 1997; 5: 1-6. (Pubitemid 27182125)
20. Blondel B, Supernant K, Du Mazaubrun C, Breart G: Trends in perinatal health in metropolitan France between 1995 and 2003: Results from the National Perinatal Surveys. J Gynecol Obstet Biol Reprod (Paris) 2006; 35: 373-387. (Pubitemid 43873121)
21. Breton P: É chographies foetales: Une crise majeure se dessine. La Presse: 22 mai, 2007, A9.
22. King ES, Rimer BK, Trock B, Balshem A, Engstrom P: How valid are mammography self-reports? Am J Public Health 1990; 80: 1386-1388. (Pubitemid 20375565)
23. Caplan LS, McQueen DV, Qualters JR, Leff M, Garrett C, Calonge N: Validity of women's self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiol Biomarkers Prev 2003; 12: 1182-1187. (Pubitemid 37499441)
24. Brett J, Austoker J, Ong G: Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. J Public Health Med 1998; 20: 396-403. (Pubitemid 29017247)
25. Gram IT, Slenker SE: Cancer anxiety and attitudes toward mammography among screening attenders, nonattenders, and women never invited. Am J Public Health 1992; 82: 249-251.
26. Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF: Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 1991; 114: 657-661.
27. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW: Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338: 1089-1096. (Pubitemid 28227478)
28. NIH Consensus Development Panel on Ovarian Cancer: NIH consensus conference: Ovarian cancer. Screening, treatment, and follow-up. JAMA 1995; 273: 491-497.
29. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice Jr. JD: Radiation effects on breast cancer risk: A pooled analysis of eight cohorts. Radiat Res 2002; 158: 220-235. (Pubitemid 34851818)
30. Berrington de Gonzalez A, Reeves G: Mammographic screening before age 50 years in the UK: Comparison of the radiation risks with the mortality benefits. Br J Cancer 2005; 93: 590-596. (Pubitemid 43080004)
31. Pharoah PD, Antoniou AC, Easton DF, Ponder BA: Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-2803. (Pubitemid 351930854)